reneuron group plc rqe buy pt allogen stem cell stroke disabl retin pigmentosa initi
coverag buy rate pt analyst jason mccarthi ph full summari
vertex pharmaceut incorpor hold anoth cf domin continu valuat peak
downgrad share hold analyst jason mccarthi ph full summari
mileston scientif inc mlss buy pt offer provid month reduc pt data
pitney bow inc buy pt ep dividend cut buy-back increas shift growth track
maintain buy lower estim pt analyst allen klee cfa full summari
inc atnm buy pt second combin trial underway r/r aml actimab-a
moleculin biotech inc mbrx buy pt grant orphan design glioblastoma
neurotrop inc ntrp buy pt could follow blood cancer potenti opportun bryostatin
corpor event call maxim salesperson inform
charl colvard ltd cthr ndr new york ceo/presid suzann miglucci cfo clint pete tue feb
onconova ontx cover mccarthi kol breakfast event nyc dr lewi silverman dr
rajwanth veluswami thu feb et
athersi inc cover mccarthi ndr nyc ceo gil van bokkelen thu feb
sintx technolog inc sint ndr new york ceo sonni bal vice-president oper david brian mon-tu
bioporto a/ biopor ndr new york ceo peter morch cfo ole larson fri feb
biotim inc cover mccarthi ndr nyc ceo brian culley cfo brandi robert tue feb
intec pharma ntec cover mccarthi kol dinner nyc ceo jeffrey meckler dr karl kierbutz dr
chesapeak util corpor cover sullivan ndr milwauke cfo beth cooper treasur
chesapeak util corpor cover sullivan ndr chicago cfo beth cooper treasur
global inc cover sullivan ndr nyc ceo dickerson wright fri feb
cover sullivan ndr boston ceo denni sadlowski cfo matthew
genco ship trade ltd cover jang ndr chicago ceo john wobensmith cfo
navig hold ltd nvg cover jang group luncheon new york ceo david butter thu
pm
cover jang ndr boston ceo gari vogel cfo frank decostanzo
director strategi busi develop costa tsoutsoplid tue apr
inc cover confer call cfo tonya robinson director
financi analysi michael bailen mon pm et
univers mcloud corpor mcld cover chokshi ndr new york ceo russ mcmeekin mon-w
univers mcloud corpor mcld cover chokshi ndr greater miami ceo russ mcmeekin wed
corpor ctrl cover chokshi ndr chicago cfo mark novakovich mon feb
corpor ctrl cover chokshi ndr boston cfo mark novakovich tue feb
sifi technolog limit sifi cover klee ndr nyc svp financ gangadharan venugop wed
agilysi inc cover klee ndr chicago cfo toni pritchett vice-president financ dave wood thu
cover klee ndr chicago presid ceo michael prior cfo justin
cover klee ndr milwauke presid ceo michael prior cfo
anoth cf domin continu
valuat peak downgrad share hold
vertex report cystic fibrosi cf revenu repres
sequenti growth beat consensu result includ
kalydeco revenu vs consensu orkambi vs
consensu symdeko vs consensu total cf
revenu y/i non-gaap opex
vertex end year cash non-gaap ep beat
consensu
guidanc total cf revenu non-gaap opex
anoth great quarter year vertex cf franchis like
continu grow symdeko symkevi launch ramp us eu
tripl combin move closer approv turn share
continu rise approach price target question
much higher valuat go well vertex
domin cf continu lower rate hold buy
valuat pt remov prior
commerci updat symdeko launch seen swift uptak demand
elig group age symkevi launch underway eu revenu
label expans year-old patient expect orkambi
kalydeco saw label expans patient young month old
kalydeco bring total address market kalydeco orkambi
symdeko patient current vertex product kalydeco hit
mark first time also reimburs agreement
establish australia sweden denmark contribut overal
higher revenu
tripl combo plu tezacaftor ivacaftor
vertex report posit data see note link phase
trial homozygot improv vs placebo
function heterozygot improv
vs placebo trial tripl combo expect
report data win tripl expect submit nda
note approv therapi approv
would bring total address popul
pain inhibitor posit data multipl pain indic
acut pain bunionectomi surgeri chronic pain caus osteoarthr
small fiber nephropathi dose rang studi bunionectomi pain on-going
support potenti pivot develop data addit pain asset enter
clinic
disord clinic develop initi decemb patient across
us eu addit asset pre-clin develop
sickl cell diseas scd thalassemia crispr gene edit
collabor crispr crsp nr track scd
trial underway indic
model chang model updat reflect guidanc non-gaap ep
estim increas
also remov pt lower rate hold buy valuat
click full note
